Arthur Kirsch

Arthur S.
Kirsch is currently an Independent Director at Liquidia Technologies, Inc. since 2016, an Independent Director at Liquidia Corp.
since 2020, a Director at Anavasi Diagnostics since 2022, an Independent Non-Executive Director at Evommune, Inc. starting in 2025, and an Independent Director at Atea Pharmaceuticals, Inc. starting in 2025.
Former positions include President & Chief Executive Officer at Natwest Securities Corp.
from 1990 to 1993, Chairman at POZEN, Inc. from 2015 to 2016, Independent Chairman at Old API Wind-down Ltd. from 2016 to 2019, Independent Director at Immunomedics, Inc. from 2015 to 2016, Director at PhysioSonics, Inc., Independent Director at Kadmon Holdings, Inc. from 2019 to 2021, Executive Vice President & Head-Equity Division at Drexel Burnham Lambert, Inc. from 1979 to 1990, President at NatWest Securities Ltd. from 1990 to 1993, Executive Vice President & Head-Research at Vector Securities LLC from 1994 to 2004, and MD, Head-Healthcare Research & Capital Markets at Prudential Vector Healthcare Group from 1999 to 2001.
Education includes undergraduate studies at the University of Rhode Island and an MBA from Baruch College.